KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) EBT (2016 - 2025)

Vertex Pharmaceuticals has reported EBT over the past 17 years, most recently at $1.3 billion for Q4 2025.

  • Quarterly results put EBT at $1.3 billion for Q4 2025, up 17.11% from a year ago — trailing twelve months through Dec 2025 was $4.6 billion (up 1768.49% YoY), and the annual figure for FY2025 was $4.6 billion, up 1768.49%.
  • EBT for Q4 2025 was $1.3 billion at Vertex Pharmaceuticals, up from $1.3 billion in the prior quarter.
  • Over the last five years, EBT for VRTX hit a ceiling of $1.3 billion in Q4 2025 and a floor of -$3.4 billion in Q2 2024.
  • Median EBT over the past 5 years was $1.1 billion (2021), compared with a mean of $811.7 million.
  • Biggest five-year swings in EBT: skyrocketed 2417.65% in 2022 and later tumbled 391.97% in 2024.
  • Vertex Pharmaceuticals' EBT stood at $870.9 million in 2021, then increased by 23.64% to $1.1 billion in 2022, then increased by 6.58% to $1.1 billion in 2023, then dropped by 0.97% to $1.1 billion in 2024, then increased by 17.11% to $1.3 billion in 2025.
  • The last three reported values for EBT were $1.3 billion (Q4 2025), $1.3 billion (Q3 2025), and $1.3 billion (Q2 2025) per Business Quant data.